KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $432.0 million.

  • Biogen's Accounts Payables rose 183.88% to $432.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $432.0 million, marking a year-over-year increase of 183.88%. This contributed to the annual value of $432.0 million for FY2025, which is 183.88% up from last year.
  • Per Biogen's latest filing, its Accounts Payables stood at $432.0 million for Q4 2025, which was up 183.88% from $413.1 million recorded in Q3 2025.
  • In the past 5 years, Biogen's Accounts Payables registered a high of $589.2 million during Q4 2021, and its lowest value of $354.5 million during Q2 2024.
  • In the last 5 years, Biogen's Accounts Payables had a median value of $423.4 million in 2024 and averaged $427.2 million.
  • In the last 5 years, Biogen's Accounts Payables soared by 2952.3% in 2021 and then plummeted by 2121.34% in 2024.
  • Quarter analysis of 5 years shows Biogen's Accounts Payables stood at $589.2 million in 2021, then dropped by 16.58% to $491.5 million in 2022, then fell by 17.95% to $403.3 million in 2023, then rose by 5.18% to $424.2 million in 2024, then grew by 1.84% to $432.0 million in 2025.
  • Its last three reported values are $432.0 million in Q4 2025, $413.1 million for Q3 2025, and $408.4 million during Q2 2025.